Hyderabad-based Bharat Biotech said the timeline for manufacturing, testing and release for a batch of Covaxin is around 120 days, depending on the technology framework and regulatory guidelines to be met
Hester Biosciences to produce Bharat Biotech s Covaxin
The MoU stated that Hester will provide complete infrastructure to manufacture the indigenously developed anti-COVID vaccine
BusinessToday.In | May 28, 2021 | Updated 12:06 IST
Ahmedabad-based Hester Biosciences will produce 20 million doses of Bharat Biotech s COVID-19 vaccine Covaxin per month from August 2021. A memorandum of understanding (MoU) has been inked between the Hyderabad-based pharma giant Bharat Biotech and Gujarat COVID Vaccine Consortium (GCVC) regarding the same.
GCVC comprises Gujarat Biotechnology Research Centre (GBRC), Hester Biosciences and Omnibrx Biotechnologies, Hester stated in a regulatory filing.
Bharat Biotech will provide production technology of the drug substance for Covaxin and GBRC will act as an advisor, mentor, and shall facilitate technology transfer from Bharat Biotech, as per this MoU. The MoU added Hester will provide complete infrastructure to manufacture the indigenously develope
URL copied
Govt exploring possibility of Covaxin production outside India
To address the shortage of COVID-19 jabs in the country, the government is exploring the possibility of boosting production of vaccines, including identifying manufacturing sites for indigenously developed Covaxin outside India, sources said. The government also intends to take up the matter with the World Health Organisation (WHO) to step up Covaxin production.
It will also take up with Moderna, Johnson and Johnson and other vaccine makers the issue of granting voluntary licence to third-party manufacturers in India on transfer of technology basis.
These issues were discussed in an inter-ministerial meeting on May 18 to deliberate upon the options, including voluntary licence, compulsory licence and government use authorisation under the Patents Act, 1970, available to increase the availability of drugs and vaccines used for treatment of COVID-19.
Bharat Biotech ropes in subsidiary to scale up Covaxin production, estimates nearly 1 billion doses per annum
As of now, Bharat Biotech is manufacturing only about 1.5 crore doses of Covaxin per month which is likely to go up to 4-5 crore doses per month by July.
Share Via Email
| A+A A- By Express News Service
NEW DELHI: Bharat Biotech on Thursday announced its plan to rope in its wholly owned subsidiary Chiron Behring for speed up production of Covaxin, India’s first and only indigenously developed COVID-19 vaccine so far, by an additional 20 crore doses per year.
This will effectively take the volumes of Covaxin to nearly 1 billion doses per annum, produced at the company s own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety, claimed the firm.